SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research
6 April 2020
CEO urges all groups researching nucleic acid based vaccines or exploring the use of antivirals for treatment to contact them
Within SiSaf’s advanced pipeline, Bio-Courier technology has demonstrated significant improvements in the stability and targeting of nucleic acid based therapies including siRNA, mRNA, CRISPR gene editing, as well as multiple peptides and small molecule drugs.
CEO, Dr Suzanne Saffie-Siebert, PhD, said, “I’m keen for SiSaf to fulfil its public health obligation in addressing the coronavirus pandemic in as many ways as possible. SiSaf’s R&D team is uniquely positioned to support groups and help accelerate their programs, not only nucleic acid based vaccine developers, but also groups exploring the use of antivirals and CD8 targets for treatment. We welcome collaboration with all groups in this race.
“Time is of the essence, so I urge relevant health organisation and research groups to contact us. Then we can rapidly assess whether our technology can help and make our resources available on a not-for-profit basis.
“We believe that the more approaches we explore, the better our likelihood of success to check the coronavirus challenge and prevent or manage future pandemics.”
About SiSaf Ltd.
SiSaf is a pioneer of silicon-based hybrid technologies. Built upon a decade of research and patented technological innovation, SiSaf’s platform is changing the way therapeutic molecules target disease, helping to make tomorrow’s precision medicines a reality. SiSaf is a commercial stage biopharmaceutical company headquartered in Guildford, UK, with fully integrated state-of-the-art research labs, manufacturing and bio-analytical facilities to fast track development.
About Bio-Courier® Technology
SiSaf’s first-to-market Bio-Courier platform technology leverages the unique properties of bioabsorbable silicon, lipids and amino acids to address the significant challenges of stability, solubility, targeting and controlled release of complex therapeutic molecules.
Its customizable design and fabrication provide unparalleled flexibility with respect to therapeutic molecule type and target cell location. Bio-Couriers degrade to the bioavailable form of silicon, eliminating the accumulation of potentially toxic or immune-activating material and supporting cell health. Cost-effective, scaled manufacturing provides unequalled capacity to address both rare diseases and large patient populations.
SiSaf owns the intellectual property of several technologies that address the significant challenges of stability, solubility, targeting and controlled release of complex therapeutic molecules.
To learn more, please visit www.sisaf.com